Last reviewed · How we verify
carboxymethylcellulose-based lubricant eye drops
Carboxymethylcellulose acts as a viscous lubricant that coats and protects the ocular surface, mimicking natural tears to relieve dryness and irritation.
Carboxymethylcellulose acts as a viscous lubricant that coats and protects the ocular surface, mimicking natural tears to relieve dryness and irritation. Used for Dry eye disease / keratoconjunctivitis sicca, Ocular surface irritation and discomfort.
At a glance
| Generic name | carboxymethylcellulose-based lubricant eye drops |
|---|---|
| Also known as | Refresh OPTIVE® Advanced |
| Sponsor | Allergan |
| Drug class | Artificial tear / lubricating agent |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | FDA-approved |
Mechanism of action
Carboxymethylcellulose (CMC) is a cellulose derivative that forms a protective film over the cornea and conjunctiva. By increasing tear film viscosity and stability, it reduces evaporation and provides prolonged lubrication and comfort. This mechanical action addresses symptoms of dry eye disease without targeting specific molecular pathways.
Approved indications
- Dry eye disease / keratoconjunctivitis sicca
- Ocular surface irritation and discomfort
Common side effects
- Transient blurred vision
- Eye irritation or stinging
- Conjunctival hyperemia
Key clinical trials
- Comparative Efficacy of Lipid Based Artificial Tears vs Aqueous Based Artificial Tears in Managing EDE (NA)
- Tear Lipid Layer Thickness With Emollient Eye Drops (PHASE4)
- Investigation of Maintaining Visual Performance Achieved With Cyclosporine Therapy (PHASE4)
- Safety, Efficacy, and Acceptability Study of an Eye Drop Formulation in Subjects With Dry Eye Disease (PHASE3)
- Bevacizumab Injection for Recurrent Pterygium
- A Study to Compare a New Eye Drop Formulation With Systane® Gel Drops and Genteal® Lubricant Gel Drops for Moderate to Severe Dry Eye Relief (PHASE3)
- A Study to Compare the Safety and Efficacy of A New Eye Drop Formulation With OPTIVE™ in Subjects With Dry Eye Disease (PHASE3)
- Safety and Tolerability of Artificial Tears in Dry Eye Subjects (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: